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The aim of this study was evaluate the predictive value of a 2 week course of prednisolone on the effect of 6 months 
treatment with inhaled budesonide in patients with stable chronic obstructive pulmonary disease (COPD). 
Forty patients with stable COPD entered the study, and received prednisolone (37.5 mg o.d.) for 2 weeks. They 
were subsequently divided into steroid-irreversible and steroid-irreversible, using 15% of baseline as a dividing 
point. In each group patients were randomized to receive budesonide 400 pg b.i.d. or placebo for 6 months. 
During treatment with prednisolone, three patients dropped out because of side effects. Of the remaining 37, only 
two patients (5%) were reversible with prednisolone forced expiratory volume in Is [(FEVi) > 15% of baseline], 
and among the steroid-irreversible, 26 patients were evaluated after 6 months treatment with either placebo or 
budesonide. No significant differences in spirometry values, symptoms, or number of exacerbations were found 
between these two groups. 
Reversibility with prednisolone is rarely seen in COPD. In outpatients with stable COPD and no signs of asthma 
or atopy, 2 weeks treatment with prednisolone seems to be of no value in choosing subsequent long-term therapy. 
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Introduction 
The use of corticosteroids is a well established part of 
treatment for asthma (1,2), whereas their use in chronic 
obstructive pulmonary disease (COPD) is still debated 
(3,4). Inflammation in asthma, and COPD is distinctly 
different and therefore corticosteroids would be expected to 
be less effective in this latter disease. 
exclusion criteria (no asthmatics included) concluded that 
subjects who received corticosteroid treatment were ap- 
proximately 10% more likely to experience an increase 20% 
or more in the baseline FEV, compared with those who 
received placebo (8). Only one of these 10 studies lasted 2 
weeks. The average prednisolone dose was 35-40 mg daily. 
For many years, the use of treatment with systemic 
corticosteroids of short-duration has been one of the 
methods that distinguished asthma from COPD, and was 
a method used to select patients with COPD, who would 
probably benefit from long-term treatment with inhaled 
corticosteroids ($6). The short duration oral steroid test is 
frequently used to ascertain if there is an asthmatic 
component in the disease. 
The clinical implication of a significant increase in FEVi 
during l-2 weeks of prednisolone treatment is still debated. 
No controlled trails have shown that these ‘steroid- 
reversible’ COPD patients gain any benefit from long-term 
treatment with either systemic or inhaled corticosteroids on 
FEVi decline. The aim of this study was to evaluate the 
predictive value of a 2 week course of prednisolone on the 
effect of 6 months treatment with inhaled budesonide in 
patients with stable COPD. 
Several randomized, placebo-controlled, double-blind 
clinical trials have evaluated systemic corticosteroids in 
stable COPD, but with a wide variation in design and 
quality (7). A recent meta-analysis of 10 randomized, 
double-blind placebo-controlled trials with well-defined 
Material and methods 
Paper received 16 November 1998 and accepted in revised form 9 
June 1999. 
This study was a placebo-controlled, randomized, double- 
blind multicentre trial, conducted at five centres in Denmark. 
Standard spirometry (VitalographTM) was performed on 
possible study subjects before the start of the study. 
Outpatients aged 18-75 years with stable COPD were 
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included. Stable COPD was defined as a FEV1, forced vital 
capacity (FVC) < 0.7, a post-bfonchodilator FEVl < 70% 
of predicted, FEVl >40% of predicted and an increase in 
FEVl < 15% after inhalation of O-5 mg terbutaline, via a 
dry poweder inhaler (Bricanyl TurbuhalerTM). At the first 
visit, a blood sample was drawn for analysis of eosinophil 
count and total blood-IgE concentration (the latter 
quantitated by an immunological reaction in which specific 
rabbit anti-IgE antibodies react with human IgE-antigen). 
The exclusion criteria were clinical evidence of asthma (e.g. 
pollen season related symptoms, exercise-induced symp- 
toms only and significantly elevated levels of eosinophils 
and IgE), a history of atopy (hay fever and/or atopic 
dermatitis), treatment with inhaled corticosteroids within 
the last 6 months, treatment with oral corticosteroids, 
chromoglycate or nedocromil within the last 4 weeks, other 
systemic disease making compliance and participation in 
the study difficult, pregnancy and breast feeding, and an 
increase in FEV, >30% of baseline after 2 weeks of 
prednisolone treatment. 
All patients received 2 weeks treatment with oral 
prednisolone 37.5 mg daily. Reversible patients with 15% 
< AFEVl < 30% of baseline and irreversible patients 
with AFEV, < 15% were separately randomized to either 
inhaled budesonide 400 pg b.i.d. or placebo (SpirocortTM 
TurbuhalerTM, Astra Danmark A/S). Spirometric values, 
number of exacerbations, symptom score and adverse 
events were recorded at monthly visits at the respiratory 
outpatient clinics. All patients gave written informed 
consent. The study was approved by the local ethics 
committees and conducted in accordance with the declara- 
tion of Helsinki. 
The primary effect parameter was a change in FEV, and 
for a study power of 90%; a total of 120 patients were 
needed to detect a difference of 100 ml at the 5% 
significance level. 
Non-parametric statistical methods (Mann-Whitney U- 
test) were used, as data were not normally distributed. 
Results 
A total of 40 patients were included in the study. Median 
FEVl was 1.49 1 (range 0.8-2.45 1). None of the patients had 
clinical evident asthma, atopy or elevated eosinophils/IgE. 
All were irreversible (AFEV, < 15% of baseline) with the 
inhaled firagonist. All but one were either smokers or ex- 
smokers, the exception being a woman married to a heavy 
smoker. The flow of evaluable patients and drop-outs is 
schematically shown in Fig. 1. 
All patients started treatment with prednisolone, but 
three patients were withdrawn because of side effects caused 
by prednisolone (restlessness and insomnia). Of the 37 
patients who completed 2 weeks prednisolone treatment, 
only two patients (5%) were found to be reversible 
(AFEVl> 15% of baseline). During the subsequent 6 
months treatment with budesonide or placebo, one of the 
patients in the ‘reversibility’ group dropped out without 
explanation, and thus only one patient completed 6 months 
of treatment. Because of the very low number of patients in 
n = 3 drop-outs because of 
prednisolone adverse events 
n = 37 completed corticosteroid reversibility test 
and were subsequently random&xi 
n = 35 with no corticosteroid n = 2 with ccorticosteroid 
reversibility reversibility 
AFEV, c 15% A 15% < A FEV, c 30% 
II = 26 evaluable after 
6 months treatment with 
budesonide 400 pg b.i.d. 
n = 1 evaluable after 
6 months treatment with 
budesonide 400 pg b.i.d. 
or placebo (patient excluded 
from further analysis) 
FIG. 1. Flow chart of study population and drop-outs. 
this treatment arm, further statistical analysis comparing 
steroid-irreversible with steroid-reversible patients would be 
meaningless. 
In the steroid-irreversible group, 14 patients were 
randomized to budesonide and 12 patients received 
placebo. There were no significant differences between the 
two groups in demographic data, baseline spirometric 
values, or smoking history. In the budesonide group, eight 
were males (57%), median age was 58.5 years (range 51-74 
years), and the median FEV, was 1.46 1 (range 0-9-2.06 1). 
In the placebo group, six were males (50%)) the median age 
was 62.5 years (range 57-74 years) and median FEV, was 
1.63 1 (range 0.8-2.45 1). 
After 6 months of treatment, the median decrease in 
post-bronchodilator FEVl in the budesonide group was 
0.02 1 (range 0.25-0.23 1) compared to a median decrease of 
0.125 1 (range 0.7-0.23 1) in the placebo group, P=O.106 
(Mann-Whitney U-test). There was no difference in the 
number of exacerbations, adverse events or symptom scores 
between the active and the placebo group (P>O.4, Mann- 
Whitney U-test). 
Discussion 
In this multicentre study only 40 patients were included, a 
number well below the calculated sample size. We found 
only two patients (5%) with an increase in FEV, > 15% of 
baseline after 2 weeks of treatment with prednisolone. 
Furthermore, none of our patients were reversible to an 
inhaled &agonist. Thus, in our patients, who were 
carefully selected to be non-asthmatics without temporary 
worsening of their pulmonary disease, 2 weeks treatment 
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with systemic corticosteroids did not increase the spiro- 
metric values, nor did it improve the symptom score or the 
number of exacerbations. Thus, we were unable to carry 
out the study as originally planned. 
Some benefits have been reported from short-term use 
of inhaled corticosteroids (9,10), although their use in 
steroid-irreversible patients has recently been questioned 
(11). In a 2 year study with high-dose inhaled corticoster- 
oids, Renkema et al. showed some improvement in 
symptoms, but not in lung function among 47 COPD 
patients (12). Results from large-scale, long-term studies 
with inhaled corticosteroids are still awaited (13). 
Preliminary results from EUROSCOP, ISOLDE and the 
Copenhagen Lung Study have been presented in abstract- 
form. In EUROSCOP (budesonide 400 pg b.i.d. v.s. placebo 
for 3 years), a significant effect on FEVl was seen within 
the first 6 months, after which no significant difference in 
FEVl decline was observed. In the ISOLDE study 
(Fluticasone proprionate 500 pg b.i.d. vs. placebo for 3 
years), the same pattern was seen, although a beneficial 
effect on exacerbation rate and quality of life parameters 
was observed. In the Copenhagen Lung Study, no 
difference between placebo and steroid-groups was ob- 
served; 290 patients were treated with either placebo or 
budesonide 800+400 /lg daily during the first 6 months 
followed by either placebo or budesonide 400 pg b.i.d. for 
2.5 years. Furthermore, there seem to be different opinions 
on how to define reversibility in COPD patients (1417), 
and finally some authors believe that a few weeks’ 
treatment with corticosteroids is not enough time to detect 
steroid-responders (18). From treatment with bronchodila- 
tors it is also known whether the result of a short-term 
reversibility test necessarily correlates well with the 
patients’ self-assessment after long-term treatment (19). 
All patients in this study had a decrease in FEVl during 
the 6 months of treatment with either budesonide or 
placebo. The placebo group showed a greater decrease in 
FEV1, but there was no significant difference between the 
groups. Our findings could indicate a beneficial effect of 
inhaled budesonide in patients with stable COPD, but the 
results from large-scale long-term studies in prednisolone- 
irreversible COPD patients are needed before any conclu- 
sions can be made. 
We conclude that in patients with stable COPD (as 
judged by medical history and careful spirometric evalua- 
tion with a reversibility test to a brochodilator), and no 
history or signs of asthma or other atopic disease, there is 
no reason to conduct short-term treatment with corticos- 
teroids in order to evaluate any possible reversibility. 
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